Hikma narrows 2026 operating profit outlook to $740 million-$760 million

By Public Technologies
  • Hikma Pharmaceuticals narrowed its 2026 operating profit forecast to $740 million-$760 million from $720 million-$770 million.
  • Group revenue growth guidance remains at 2%-4%, with year-to-date performance in line with expectations.
  • Branded revenue growth guidance increased to around 10% from 6%-8%, supported by strong demand.
  • Branded core operating margin is forecast near 27%, up from around 25%, reflecting a strong product mix despite increased marketing spending.
  • Injectables revenue is now expected to remain broadly flat rather than grow by low single digits; core operating margin guidance remains 27%-28%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hikma Pharmaceuticals plc published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.